Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 26, 2025; 13(36): 114228
Published online Dec 26, 2025. doi: 10.12998/wjcc.v13.i36.114228
Published online Dec 26, 2025. doi: 10.12998/wjcc.v13.i36.114228
Chemotherapy-related cardiotoxicity: Bridging the gap between evidence and practice
Wajid Ali, Department of Medicine, Harlem Hospital Center, New York, NY 10037, United States
Aimen Mehmood, Department of Medicine, University of Cincinnati, Cincinnati, OH 45221, United States
Salim Surani, Department of Medicine, University of Houston, College Station, TX 77004, United States
Author contributions: Surani S designed the overall concept and outline of the manuscript and contributed to editing it; Wajid A contributed to the discussion and design of the manuscript, as well as to writing and editing it.
Conflict-of-interest statement: None of the authors have any conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salim Surani, MD, Department of Medicine, University of Houston, 40 Bizzell Street, College Station, TX 77004, United States. srsurani@hotmail.com
Received: September 17, 2025
Revised: October 29, 2025
Accepted: December 22, 2025
Published online: December 26, 2025
Processing time: 102 Days and 7.5 Hours
Revised: October 29, 2025
Accepted: December 22, 2025
Published online: December 26, 2025
Processing time: 102 Days and 7.5 Hours
Core Tip
Core Tip: This study shows that chemotherapy-related cardiotoxicity is underestimated when multimodal surveillance is inconsistently applied. Cardio-oncology must now move beyond sporadic imaging and biomarkers toward structured, risk-adapted protocols, particularly in low- and middle-income countries where there is a high incidence of global cancer care.